HLA Stock Overview
Healthia Limited provides health services in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.64|
|52 Week High||AU$2.44|
|52 Week Low||AU$1.26|
|1 Month Change||10.07%|
|3 Month Change||-2.96%|
|1 Year Change||-17.59%|
|3 Year Change||64.00%|
|5 Year Change||n/a|
|Change since IPO||37.24%|
Recent News & Updates
|HLA||AU Healthcare||AU Market|
Return vs Industry: HLA underperformed the Australian Healthcare industry which returned -4% over the past year.
Return vs Market: HLA underperformed the Australian Market which returned -7.9% over the past year.
|HLA Average Weekly Movement||6.4%|
|Healthcare Industry Average Movement||5.6%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.6%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: HLA is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: HLA's weekly volatility (6%) has been stable over the past year.
About the Company
Healthia Limited provides health services in Australia. The company operates 94 podiatry clinics under the My FootDr brand; 52 physiotherapy clinics; and 14 hand therapy clinics, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics. It also offers podiatry and foot and nail care products, hand and upper limb therapies, orthopaedic, optometry, pilates, retail footwear, custom orthotic manufacturing services, and medical products to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals.
Healthia Fundamentals Summary
|HLA fundamental statistics|
Is HLA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HLA income statement (TTM)|
|Cost of Revenue||AU$119.09m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 31, 2022
|Earnings per share (EPS)||0.0013|
|Net Profit Margin||0.095%|
How did HLA perform over the long term?See historical performance and comparison
2.7%Current Dividend Yield
Is HLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HLA?
Other financial metrics that can be useful for relative valuation.
|What is HLA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HLA's PS Ratio compare to its peers?
|HLA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CAJ Capitol Health
AHX Apiam Animal Health
SLA SILK Laser Australia
Price-To-Sales vs Peers: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (13.4x).
Price to Earnings Ratio vs Industry
How does HLA's PE Ratio compare vs other companies in the AU Healthcare Industry?
Price-To-Sales vs Industry: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the Australian Healthcare industry average (1.4x)
Price to Sales Ratio vs Fair Ratio
What is HLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.3x|
|Fair PS Ratio||1.4x|
Price-To-Sales vs Fair Ratio: HLA is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).
Share Price vs Fair Value
What is the Fair Price of HLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: HLA (A$1.64) is trading below our estimate of fair value (A$4.46)
Significantly Below Fair Value: HLA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLA's forecast earnings growth (32.2% per year) is above the savings rate (1.8%).
Earnings vs Market: HLA's earnings (32.2% per year) are forecast to grow faster than the Australian market (6.1% per year).
High Growth Earnings: HLA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HLA's revenue (10.1% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: HLA's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (12.3%).
Discover growth companies
How has Healthia performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLA has a large one-off loss of A$4.5M impacting its December 31 2021 financial results.
Growing Profit Margin: HLA's current net profit margins (0.1%) are lower than last year (6.6%).
Past Earnings Growth Analysis
Earnings Trend: HLA's earnings have grown significantly by 44.5% per year over the past 5 years.
Accelerating Growth: HLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: HLA had negative earnings growth (-97.7%) over the past year, making it difficult to compare to the Healthcare industry average (29.8%).
Return on Equity
High ROE: HLA's Return on Equity (1.9%) is considered low.
Discover strong past performing companies
How is Healthia's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: HLA's short term assets (A$26.7M) do not cover its short term liabilities (A$46.5M).
Long Term Liabilities: HLA's short term assets (A$26.7M) do not cover its long term liabilities (A$125.7M).
Debt to Equity History and Analysis
Debt Level: HLA's net debt to equity ratio (36.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: HLA's debt is well covered by operating cash flow (22%).
Interest Coverage: HLA's interest payments on its debt are not well covered by EBIT (3x coverage).
Discover healthy companies
What is Healthia current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HLA's dividend (2.74%) is higher than the bottom 25% of dividend payers in the Australian market (2.62%).
High Dividend: HLA's dividend (2.74%) is low compared to the top 25% of dividend payers in the Australian market (6.24%).
Stability and Growth of Payments
Stable Dividend: HLA has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: HLA's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (2772.6%), HLA's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (48.2%), HLA's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...
CEO Compensation Analysis
Compensation vs Market: Wes's total compensation ($USD276.03K) is about average for companies of similar size in the Australian market ($USD279.73K).
Compensation vs Earnings: Wes's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: HLA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: HLA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.
Healthia Limited's employee growth, exchange listings and data sources
- Name: Healthia Limited
- Ticker: HLA
- Exchange: ASX
- Founded: 2018
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: AU$210.439m
- Shares outstanding: 128.32m
- Website: https://www.healthia.com.au
- Healthia Limited
- East Tower
- Level 4
- Bowen Hills
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/08 00:00|
|End of Day Share Price||2022/08/08 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.